The presentation (a 4.5mb pdf) uses data from the report, "Safety and Efficacy of Intravenous Zanamivir in Preventing Experimental Human Influenza A Virus Infection"
http://aac.asm.org/cgi/content/full/43/7/1616
A timely reminder of IV Relenza's efficiency with the re-emergence of Tamiflu resistance "in vivo".